Inflammatory bowel disease is not associated with an increased risk of lymphoma
Inflammatory bowel disease is not associated with an increased risk of lymphoma
复制标题
DOI：
10.1053/gast.2001.28703
复制
发表时间：
2001-11-01
期刊：
影响因子：
29.4
通讯作者：
Strom, BL
中科院分区：
文献类型：
--
作者：
Lewis, JD;Bilker, WB;Strom, BL
背景和目标。先前关于炎症性肠病患者淋巴瘤风险的研究提供了相互矛盾的结果。本研究探讨了炎症性肠病患者发生何杰金氏淋巴瘤和非何杰金氏淋巴瘤的风险。方法，作者使用全科医学研究数据库进行了一项回顾性队列研究。炎症性肠病患者在年龄、性别和初级保健实践方面与随机选择的对照组相匹配。淋巴瘤发生率也与已发表的年龄和性别特异性发生率进行了比较。结果这项研究包括6605例克罗恩病患者，其中10,391例为克罗恩病患者。溃疡性结肠炎组和60，506名对照组分别平均随访3.7年、3.9年和4.4年。炎症性肠病患者淋巴瘤的发生率未增加（相对危险度= 1.20; 95%CI，0.67-2.06）。在亚组分析中，未观察到克罗恩病（相对风险= 1.39; 95% CI，0.50-3.40）或溃疡性结肠炎（相对风险= 1.11; 95% CI，0.51-2.19）患者的风险增加。与未接受硫唑嘌呤或6-MP治疗的炎症性肠病患者相比，在接受这些药物治疗的1465例炎症性肠病患者中（平均106 mg/天，持续2.0年），淋巴瘤的相对风险为1.27（95% CI 0.03-8.20）。结论：患者存在炎症性肠病。与一般人群相比，患有这种疾病的人患淋巴瘤的风险并没有增加。虽然我们不能完全排除硫唑嘌呤或6-MP治疗会适度增加淋巴瘤的风险，但在该队列中未观察到风险增加。
Background & Aims. Previous studies of the risk of lymphoma in inflammatory bowel disease patients have provided conflicting results. This study examines the risk of Hodgkin' s and non-Hodgkin's lymphoma among patients with inflammatory bowel disease. Methods., The authors performed a retrospective cohort study using the General Practice Research Database. Inflammatory bowel disease patients were matched to randomly selected controls on age, sex, and primary care practice. Lymphoma rates were also compared with published age- and sex-specific rates. Results. The study included 6605 patients with Crohn's disease, :10,391 with. ulcerative colitis, and 60,506 controls followed for an average of 3.7, 3.9, and 4.4 years, respectively. The incidence of lymphoma was not increased in patients with, inflammatory bowel disease (relative risk = 1.20; 95% Cl, 0.67-2.06). In subgroup analyses, an increased risk was not observed among patients with Crohn's disease (relative risk = 1.39; 95% Cl, 0.50-3.40) or ulcerative colitis (relative risk = 1.11; 95% Cl, 0.51-2.19). Compared with Inflammatory bowel disease patients not treated with azathioprine or 6-MP, the relative risk of lymphoma among the :1465 inflammatory bowel disease patients treated with these medications (average, 106 mg/day for 2.0 years) was 1.27 (95% CI 0.03-8.20). Conclusions: Patients with inflammatory bowel. disease do not have an increased risk of lymphoma as compared with the general population. Although we cannot completely rule out a modest increased risk of lymphoma with azathioprine or 6-MP therapy, an increased risk was not observed in this cohort.